Victory Capital Management
VKTX icon

Victory Capital Management’s Viking Therapeutics VKTX Stock Holding History

Victory Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$509K Buy
13,048
+202
+2% +$6.53K ﹤0.01% 2070
2026
Q1 		$418K Buy
12,846
+199
+2% +$6.4K ﹤0.01% 2066
2025
Q4 		$445K Buy
12,647
+79
+0.6% +$2.8K ﹤0.01% 2052
2025
Q3 		$330K Sell
12,568
-428
-3% -$12.8K ﹤0.01% 2133
2025
Q2 		$344K Sell
12,996
-144
-1% -$3.79K ﹤0.01% 2128
2025
Q1 		$317K Sell
13,140
-8,857
-40% -$280K ﹤0.01% 2124
2024
Q4 		$885K Buy
21,997
+2,689
+14% +$153K ﹤0.01% 1860
2024
Q3 		$1.22M Sell
19,308
-9,608
-33% -$564K ﹤0.01% 1700
2024
Q2 		$1.53M Sell
28,916
-163,043
-85% -$10.7M ﹤0.01% 1526
2024
Q1 		$15.7M Buy
191,959
+154,459
+412% +$6.87M 0.02% 902
2023
Q4 		$698K Buy
37,500
+3,049
+9% +$39.9K ﹤0.01% 1871
2023
Q3 		$381K Sell
34,451
-784,661
-96% -$11.2M ﹤0.01% 2061
2023
Q2 		$13.3M Buy
819,112
+553,792
+209% +$11.6M 0.01% 929
2023
Q1 		$4.42M Buy
+265,320
New +$2.74M 0.01% 1223
2021
Q4 		– Sell
-10,204
Closed -$64K – 2855
2021
Q3 		$64K Sell
10,204
-379
-4% -$2.34K ﹤0.01% 2668
2021
Q2 		$63K Sell
10,583
-86,592
-89% -$514K ﹤0.01% 2654
2021
Q1 		$615K Sell
97,175
-4,787
-5% -$33.7K ﹤0.01% 2098
2020
Q4 		$574K Sell
101,962
-5,984
-6% -$36.2K ﹤0.01% 2012
2020
Q3 		$628K Sell
107,946
-42,029
-28% -$289K ﹤0.01% 1878
2020
Q2 		$1.08M Sell
149,975
-511
-0.3% -$3.39K ﹤0.01% 1695
2020
Q1 		$704K Sell
150,486
-11,812
-7% -$72.6K ﹤0.01% 1726
2019
Q4 		$1.3M Buy
162,298
+3,618
+2% +$26.4K ﹤0.01% 1661
2019
Q3 		$1.09M Buy
158,680
+153,057
+2,722% +$1.14M ﹤0.01% 1680
2019
Q2 		$47K Hold
5,623
– – ﹤0.01% 1741
2019
Q1 		$56K Hold
5,623
– – ﹤0.01% 1703
2018
Q4 		$43K Sell
5,623
-1,071
-16% -$12.8K ﹤0.01% 1705
2018
Q3 		$117K Buy
6,694
+880
+15% +$10.5K ﹤0.01% 1652
2018
Q2 		$55K Sell
5,814
-599,980
-99% -$3.99M ﹤0.01% 1753
2018
Q1 		$2.65M Buy
605,794
+410,864
+211% +$2.27M 0.01% 996
2017
Q4 		$791K Buy
+194,930
New +$566K ﹤0.01% 1269

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Victory Capital Management's VKTX Position: Q2 2026 in Review

Victory Capital Management increased its Viking Therapeutics (VKTX) stake by 1.6% in Q2 2026, buying an estimated $6.53K and bringing the position to 13,048 shares worth $509K. The position accounts for ﹤0.01% of the portfolio, ranked #2070.

Victory Capital Management first reported a position in VKTX in Q4 2017 and has held it in 30 quarters since. The position peaked at $15.7M in Q1 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Victory Capital Management held 13,048 shares of Viking Therapeutics worth $509K as of Q2 2026.
  • Victory Capital Management bought 202 Viking Therapeutics shares in Q2 2026, an estimated $6.53K.
  • Viking Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2070 holding.
  • Victory Capital Management first reported a position in Viking Therapeutics in Q4 2017 and has held it in 30 quarters since.
  • Victory Capital Management's Viking Therapeutics position peaked at $15.7M in Q1 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.